Immuneering (NASDAQ: IMRX)
$5.95
(8.0%)
$0.44
Price as of September 8, 2025, 4:00 p.m. ET
Immuneering Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immuneering Company Info
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
News & Analysis
Featured Article
Immuneering Posts Narrower Loss in Q2
Motley Fool Markets Team | Aug 13, 2025
Featured Article
Why Shares of Immuneering Jumped This Week
Immuneering is ready to share information regarding its lead therapy.
James Halley | Mar 24, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.